Haas, Michael
Ormanns, Steffen
Baechmann, Sibylle
Remold, Anna
Kruger, Stephan
Westphalen, Christoph B
Siveke, Jens T
Wenzel, Patrick
Schlitter, Anna Melissa
Esposito, Irene
Quietzsch, Detlef
Clemens, Michael R
Kettner, Erika
Laubender, Ruediger P
Jung, Andreas
Kirchner, Thomas
Boeck, Stefan
Heinemann, Volker
Article History
Received: 23 November 2016
Revised: 21 March 2017
Accepted: 3 April 2017
First Online: 27 April 2017
Competing interests
: No direct payment was received for the current work by a company or any third parties. The follwing authors declare a potential conflict of interest: Michael Haas: Honoraria for scientific presentations: Celgene, Research funding: Roche, Boehringer, Travel accommodation expenses: Boehringer, Celgene. Andreas Jung: Honoraria for scientific presentations: Amgen, AstraZeneca, Merck, Qiagen, Roche, Travel accommodation expenses: Amgen, AstraZeneca, Merck, Qiagen, Roche. Stefan Boeck: Honoraria for scientific presentations: Roche, Celgene, Consulting or Advisory Board: Celgene, Baxalta, Research funding: Roche, Celgene, Clovis Oncology, Travel accommodation expenses: Celgene, Roche. Volker Heinemann: Honoraria for scientific presentations: Merck, Roche, Celgene, Consulting or Advisory Board: Merck, Roche Celgene, Boehringer, AMGEN, Research funding: Merck, AMGEN, Roche Celgene, Boehringer, Travel accommodation expenses: Merck, Roche. All other authors declare that they have no conflict of interest.